Assessment of packed bed bioreactor systems in the production of viral vaccines
- PMID: 24949260
- PMCID: PMC4052670
- DOI: 10.1186/s13568-014-0025-z
Assessment of packed bed bioreactor systems in the production of viral vaccines
Abstract
Vaccination is believed to be the most effective method for the prevention of infectious diseases. Thus it is imperative to develop cost effective and scalable process for the production of vaccines so as to make them affordable for mass use. In this study, performance of a novel disposable iCELLis fixed bed bioreactor system was investigated for the production of some viral vaccines like Rabies, Hepatitis-A and Chikungunya vaccines in comparison to conventional systems like the commercially available packed bed system and roller bottle system. Vero and MRC-5 cell substrates were evaluated for growth parameters in all the three systems maintaining similar seeding density, multiplicity of infection (MOI) and media components. It was observed that Vero cells showed similar growth in all the three bioreactors whereas MRC-5 cells showed better growth in iCELLis Nano system and roller bottle system. Subsequently, the virus infection and antigen production studies also revealed that for Hepatitis-A and Chikungunya iCELLis Nano bioreactor system was better to the commercial packed bed bioreactor and roller bottle systems. Although for rabies antigen production commercially available packed bed bioreactor system was found to be better. This study shows that different bioreactor platforms may be employed for viral vaccine production and iCELLis Nano is one of such new convenient and a stable platform for production of human viral vaccines.
Keywords: Chikungunya virus; Hepatitis-A virus; Packed bed bioreactor; Rabies virus; Vaccine production; iCELLis Nano bioreactor.
Figures




Similar articles
-
Vero cell upstream bioprocess development for the production of viral vectors and vaccines.Biotechnol Adv. 2020 Nov 15;44:107608. doi: 10.1016/j.biotechadv.2020.107608. Epub 2020 Aug 5. Biotechnol Adv. 2020. PMID: 32768520 Free PMC article. Review.
-
Benchmarking of Scale-X Bioreactor System in Lentiviral and Adenoviral Vector Production.Hum Gene Ther. 2020 Mar;31(5-6):376-384. doi: 10.1089/hum.2019.247. Hum Gene Ther. 2020. PMID: 32075423 Free PMC article.
-
Process Development of Adenoviral Vector Production in Fixed Bed Bioreactor: From Bench to Commercial Scale.Hum Gene Ther. 2015 Aug;26(8):560-71. doi: 10.1089/hum.2015.081. Hum Gene Ther. 2015. PMID: 26176404
-
Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density.Biotechnol Lett. 2020 Dec;42(12):2551-2560. doi: 10.1007/s10529-020-02987-x. Epub 2020 Aug 20. Biotechnol Lett. 2020. PMID: 32816175
-
Evaluation of the Single-Use Fixed-Bed Bioreactors in Scalable Virus Production.Biotechnol J. 2021 Jan;16(1):e2000020. doi: 10.1002/biot.202000020. Epub 2020 Oct 12. Biotechnol J. 2021. PMID: 32971565 Review.
Cited by
-
High-titer manufacturing of SARS-CoV-2 Spike-pseudotyped VSV in stirred-tank bioreactors.Mol Ther Methods Clin Dev. 2024 Jan 17;32(1):101189. doi: 10.1016/j.omtm.2024.101189. eCollection 2024 Mar 14. Mol Ther Methods Clin Dev. 2024. PMID: 38327804 Free PMC article.
-
Optimization of lentiviral vector production for scale-up in fixed-bed bioreactor.Gene Ther. 2018 Jan;25(1):39-46. doi: 10.1038/gt.2017.91. Epub 2017 Oct 5. Gene Ther. 2018. PMID: 29345252 Free PMC article.
-
Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.Vaccine. 2025 Apr 19;53:126950. doi: 10.1016/j.vaccine.2025.126950. Epub 2025 Mar 3. Vaccine. 2025. PMID: 40037128 Free PMC article.
-
Vero cell upstream bioprocess development for the production of viral vectors and vaccines.Biotechnol Adv. 2020 Nov 15;44:107608. doi: 10.1016/j.biotechadv.2020.107608. Epub 2020 Aug 5. Biotechnol Adv. 2020. PMID: 32768520 Free PMC article. Review.
-
Optimizing and developing a scalable, chemically defined, animal component-free lentiviral vector production process in a fixed-bed bioreactor.Mol Ther Methods Clin Dev. 2023 Jul 3;30:221-234. doi: 10.1016/j.omtm.2023.06.011. eCollection 2023 Sep 14. Mol Ther Methods Clin Dev. 2023. PMID: 37528866 Free PMC article.
References
-
- Aunins JG. In: Encylopedia of cell technology. Spier ER, editor. Wiley, New York; 2000. Viral vaccine production in cell culture; pp. 1183–1207.
-
- Butler M. Growth limitations on microcarriers. Adv Biochem Eng Biotechnol. 1987;4:57–84. - PubMed
-
- Drugmand JC, Havelange N, Debras F, Collignon F, Mathieu E, Castillo J. Vaccine production in iCELLis fixed bed disposable bioreactor. Veterinary Vaccines Düsseldorf, Germany; 2009.
-
- Drugmand JC, Dubois S, Dohogne Y, Havelange N, Castillo J. Viral vaccine production at manufacturing size into iCELLisTM disposable fixed-bed reactor. Vaccine Production Summit, La Jolla, CA, USA; 2010.
LinkOut - more resources
Full Text Sources
Other Literature Sources